8476 - 8500 of 9146 Results
Title
Year
- The transition between turning and sitting in patients with Parkinson's disease: A wearable device detects an unexpected sequence of events2018RESTRICTEDTitle: The transition between turning and sitting in patients with Parkinson's disease: A wearable device detects an unexpected sequence of eventsJournal Name: Gait & PosturePublisher: Elsevier BVVol: 67Issue #:Start Page: 224End Page: 229Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.gaitpost.2018.10.018Citation Count: 35
- Valbenazine as treatment for Huntington's disease chorea2023RESTRICTEDTitle: Valbenazine as treatment for Huntington's disease choreaJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 22Issue #: 6Start Page: 459End Page: 460Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00163-1Citation Count: 5
- α-synuclein seed amplification in Parkinson‘s disease2023RESTRICTEDTitle: α-synuclein seed amplification in Parkinson‘s diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 22Issue #: 11Start Page: 985End Page: 985Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00373-3Citation Count: 3
-
OPENTitle: Epigenomic profile of GBA1 in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 140Issue #:Start Page: 108066End Page: 108066Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2025.108066Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12825421/Citation Count: 1
- Exosome/microvesicle content is altered in leucine‐rich repeat kinase 2 mutant induced pluripotent stem cell‐derived neural cells2019RESTRICTEDTitle: Exosome/microvesicle content is altered in leucine‐rich repeat kinase 2 mutant induced pluripotent stem cell‐derived neural cellsJournal Name: Journal of Comparative NeurologyPublisher: WileyVol: 528Issue #: 7Start Page: 1203End Page: 1215Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/cne.24819Citation Count: 16
- REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers2015OPENTitle: REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriersJournal Name: Movement DisordersPublisher: WileyVol: 30Issue #: 13Start Page: 1834End Page: 1839Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.26413Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/4715645Citation Count: 41
-
OPENTitle: Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liabilityJournal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 28Issue #: 15Start Page: 2641End Page: 2646Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2018.06.034Best OA location URL: https://doi.org/10.7270/q2dr2z5hCitation Count: 14
-
OPENTitle: The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson's disease: The mobilise-D studyJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 16Issue #: 1Start Page: 110End Page: 124Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/1877718x251407026Best OA location URL: https://doi.org/10.1177/1877718x251407026Citation Count: 4
- High priority publications on Parkinson's disease in 20172017RESTRICTEDTitle: High priority publications on Parkinson's disease in 2017Journal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 17Issue #: 1Start Page: 8End Page: 10Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(17)30416-7Citation Count: 0
- In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease2023OPENTitle: In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 198End Page: 198Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29315Best OA location URL: https://doi.org/10.1002/mds.29315Citation Count: 2
-
OPENTitle: Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau FibrilsJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 12Issue #: 18Start Page: 3487End Page: 3496Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1021/acschemneuro.1c00536Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.1c00536Citation Count: 24
- Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies2017RESTRICTEDTitle: Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathiesJournal Name: Clinica Chimica ActaPublisher: Elsevier BVVol: 466Issue #:Start Page: 152End Page: 159Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.cca.2017.01.010Citation Count: 30
-
OPENTitle: Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 34Issue #:Start Page: 15End Page: 19Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2016.10.006Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/5222688Citation Count: 40
-
OPENTitle: A high-content imaging workflow to screen for molecules that reduce cellular uptake of α-synuclein preformed fibrilsJournal Name: MethodsPublisher: Elsevier BVVol: 252Issue #:Start Page: 41End Page: 54Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ymeth.2026.05.001Best OA location URL: https://doi.org/10.1016/j.ymeth.2026.05.001Citation Count: 0
-
OPENTitle: Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson’s DiseaseJournal Name: eneuroPublisher: Society for NeuroscienceVol: 8Issue #: 4Start Page: ENEURO.0559End Page: 20.2021Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1523/eneuro.0559-20.2021Best OA location URL: https://www.eneuro.org/content/eneuro/8/4/ENEURO.0559-20.2021.full.pdfCitation Count: 14
-
OPENTitle: Targeting Rab‐RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's diseaseJournal Name: Journal of Peptide SciencePublisher: WileyVol: 30Issue #: 5Start Page: e3563End Page: e3563Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/psc.3563Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psc.3563Citation Count: 4
-
OPENTitle: Testing the Protein Propagation Hypothesis of Parkinson DiseaseJournal Name: Journal of Experimental NeurosciencePublisher: SAGE PublicationsVol: 12Issue #:Start Page: 1179069518786715End Page: 1179069518786715Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/1179069518786715Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/1179069518786715Citation Count: 33
-
OPENTitle: A comprehensive cognitive analysis of cervical dystonia: A single centre studyJournal Name: Clinical Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 9Issue #:Start Page: 100226End Page: 100226Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.prdoa.2023.100226Best OA location URL: https://doi.org/10.1016/j.prdoa.2023.100226Citation Count: 3
- The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease2026OPENTitle: The challenges of experimental pharmacology in identifying novel treatments for Parkinson's diseaseJournal Name: Current Opinion in NeurobiologyPublisher: Elsevier BVVol: 97Issue #:Start Page: 103164End Page: 103164Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.conb.2025.103164Best OA location URL: https://doi.org/10.1016/j.conb.2025.103164Citation Count: 2
- Parkinson's Disease Detection on DaTscan Images Using Random Forest and Graph Deep Learning2025RESTRICTEDTitle: Parkinson's Disease Detection on DaTscan Images Using Random Forest and Graph Deep LearningJournal Name: 2025 33rd European Signal Processing Conference (EUSIPCO)Publisher: IEEEVol:Issue #:Start Page: 1577End Page: 1581Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.23919/eusipco63237.2025.11226573Citation Count: 0
-
OPENTitle: Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreJournal Name: European Journal of NeurosciencePublisher: WileyVol: 45Issue #: 1Start Page: 175End Page: 191Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1111/ejn.13476Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejn.13476Citation Count: 27
- Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease2017RESTRICTEDTitle: Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 41Issue #:Start Page: 104End Page: 108Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2017.05.023Citation Count: 9
-
OPENTitle: LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson diseaseJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 15Start Page: 2536End Page: 2541Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.23314Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/2978749Citation Count: 70
-
OPENTitle: Cerebral dopamine neurotrophic factor and its functional fragments induce calcium signal through sigma-1 receptor and protect neurons against glutamate-induced excitotoxicityJournal Name: Biomedicine & PharmacotherapyPublisher: Elsevier BVVol: 195Issue #:Start Page: 119034End Page: 119034Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.biopha.2026.119034Best OA location URL: https://doi.org/10.1016/j.biopha.2026.119034Citation Count: 0
- Increased Dynamics of α-Synuclein Fibrils by β-Synuclein Leads to Reduced Seeding and Cytotoxicity2019OPENTitle: Increased Dynamics of α-Synuclein Fibrils by β-Synuclein Leads to Reduced Seeding and CytotoxicityJournal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page: 17579End Page: 17579Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-019-54063-8Best OA location URL: https://www.nature.com/articles/s41598-019-54063-8.pdfCitation Count: 23